When is this exam indicated?
The PSA test is requested at the discretion of the examining urologist. The decision to perform this test should be discussed with the patient, investigating the possible benefits and risks. It is possible to measure PSA for men aged 45-50 years and older who undergo regular andrological check-ups, evaluating this threshold according to concomitant factors such as the occurrence of prostate cancer in the family.
How is it performed?
The examination requires a simple blood test.
 Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16. doi:10.1056/NEJM198710083171501.
 Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free and total prostate specific antigen in serum of patients with prostate carcinoma and benign prostatic hyperplasia. Cancer 1997;79:104-9.
 Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008;179:2181-6. doi:10.1016/j.juro.2008.01.099.
 Huang Y, Li Z-Z, Huang Y-L, Song H-J, Wang Y-J. Value of free/total prostate specific antigen (f/t PSA) ratios for prostate cancer detection in patients with serum total prostate specific antigen between 4 and 10 ng/mL: a meta-analysis. Medicine (Baltimore) 2018;97:e0249. doi:10.1097/MD.00000000010249.
 Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of prostate-specific antigen free rate to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7. doi:10.1001/jama.279.19.1542.
 Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, et al. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and prostate health index) for prostate cancer detection: A review of the literature. Korean J Urol 2014. doi:10.4111/kju.2014.55.7.436.
 Fossati N, Lazzeri M, Haese A, McNicholas T, De La Taille A, Buffi NM, et al. Clinical performance of the serum [-2]proPSA isoform (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: Results of a European multicenter study. BJU Int 2015. doi:10.1111/bju.12718.
 Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy with prostate cancer: Results of a European multicenter prospective study. Eur Urol 2015. doi:10.1016/j.eururo.2014.07.034.
 Lazzeri M, Abrate A, Lughezzani G, Gadda GM, Freschi M, Mistretta F, et al. Relationship of chronic histological prostate inflammation in biopsy specimens with serum [-2]proPSA isoform (p2PSA), %p2PSA, and prostate health index in men with total prostate specific antigen of 4-10 ng/mL and normal digital rectal examination. Urology 2014. doi:10.1016/j.urology.2013.10.016.